In order to better simulate the normal pancreatic insulin secretion pattern, reduce blood glucose fluctuations, and lower the risk of hypoglycemia in type 1 diabetes patients, the development of an artificial pancreas system (APS) for blood glucose management has emerged. This evidence concerns the gene INS and type 1 diabetes mellitus.